Connor, Clark & Lunn Investment Management (CC&L)
ACRS icon

Connor, Clark & Lunn Investment Management (CC&L)’s Aclaris Therapeutics ACRS Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.4M Sell
1,209,886
-208,474
-15% -$930K 0.01% 649
2026
Q1 		$5.32M Sell
1,418,360
-15,804
-1% -$53.3K 0.01% 670
2025
Q4 		$4.32M Buy
1,434,164
+366,508
+34% +$926K 0.01% 693
2025
Q3 		$2.03M Buy
1,067,656
+270,522
+34% +$472K 0.01% 850
2025
Q2 		$1.13M Sell
797,134
-67,877
-8% -$91.9K ﹤0.01% 1015
2025
Q1 		$1.32M Sell
865,011
-43,808
-5% -$93.4K 0.01% 861
2024
Q4 		$2.25M Buy
908,819
+576,413
+173% +$1.43M 0.01% 695
2024
Q3 		$382K Buy
332,406
+216,826
+188% +$266K ﹤0.01% 1165
2024
Q2 		$127K Buy
115,580
+14,807
+15% +$17.4K ﹤0.01% 1296
2024
Q1 		$125K Buy
+100,773
New +$120K ﹤0.01% 1449
2023
Q4 		– Sell
-201,233
Closed -$1.38M – 1359
2023
Q3 		$1.38M Sell
201,233
-9,604
-5% -$82.1K 0.01% 720
2023
Q2 		$2.19M Buy
210,837
+34,187
+19% +$309K 0.01% 592
2023
Q1 		$1.43M Buy
176,650
+159,804
+949% +$2.03M 0.01% 629
2022
Q4 		$265K Sell
16,846
-10,008
-37% -$161K ﹤0.01% 998
2022
Q3 		$423K Buy
+26,854
New +$423K ﹤0.01% 852
2020
Q4 		– Sell
-31,575
Closed -$81K – 884
2020
Q3 		$81K Buy
+31,575
New +$70.7K ﹤0.01% 881

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ACRS Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Aclaris Therapeutics (ACRS) stake by 15% in Q2 2026, selling an estimated $930K and leaving 1,209,886 shares worth $6.4M. The position accounts for 0.01% of the portfolio, ranked #649.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ACRS in Q3 2020 and has held it in 16 quarters since. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 1,209,886 shares of Aclaris Therapeutics worth $6.4M as of Q2 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 208,474 Aclaris Therapeutics shares in Q2 2026, an estimated $930K.
  • Aclaris Therapeutics made up 0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #649 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Aclaris Therapeutics in Q3 2020 and has held it in 16 quarters since.
  • 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.